Mylan’s sudden plans for a generic EpiPen
From the post:
Obviously Mylan didn't want to underprice its own branded drug, but it's possible they had filed away plans for a generic version in case a significant competitor arose. Rachel Sachs, an associate professor at Washington University School of Law in St. Louis, points out that Mylan likely drew up generic plans to rival Israel-based Teva Pharmaceutical Industries, which has faced difficulty in gaining approval for a generic epinephrine auto-injector.
“It may well have been on the list of things they were considering, especially when it looked like Teva was going to get approval,” said Sachs, a health law expert. “They probably had some amount of that ready to go, only now in a week of intense media scrutiny did they actually complete that step.”